(Q44961269)

7 December 2017

title

The activity of antiepileptic drugs as histone deacetylase inhibitors (English)

1 reference

7 December 2017

1

1 reference

7 December 2017

Boris Yagen

2

1 reference

7 December 2017

Eyal Sobol

3

1 reference

7 December 2017

Yoram Altschuler

4

1 reference

7 December 2017

Miriam Shmuel

5

1 reference

7 December 2017

Meir Bialer

6

1 reference

7 December 2017

publication date

1 July 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

45

1 reference

7 December 2017

issue

7

1 reference

7 December 2017

page(s)

737-744

1 reference

New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Glucocorticoid-regulated transcription factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

New visions in the pharmacology of anticonvulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

HeLa cells 50 years on: the good, the bad and the ugly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Cloning and characterization of a novel human histone deacetylase, HDAC8

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

A role for histone deacetylase activity in HDAC1-mediated transcriptional repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Therapeutic drug monitoring of the newer antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0013-9580.2004.00104.X

10.1111/J.0013-9580.2004.00104.X

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference